摘要
目的:观察含左西孟旦(Levo)的停搏液对大鼠离体缺血再灌注心肌的保护作用。方法:32只雄性Wistar大鼠随机分为L0、L0.03、L0.3、LG共4组,每组8只,在去极化停搏液STH-2中分别加入Levo0、0.03、0.3μmol/L以及Levo0.3μmol/L+格列苯脲10μmol/L。平衡灌注30min后分别用25℃的4种不同停搏液停搏,2h后重新灌注30min,观察对比各组停搏前后不同时间点心功能指标、再灌注末冠脉流出液中乳酸脱氢酶(LDH)和肌酸激酶(CK)含量的不同。结果:各组心功能基础值差异无统计学意义(P>0.05),再灌注期各组心功能都有不同程度的降低,L0.3组左心室舒张末压(LVDP)、心室内压力上升/下降速率(±dp/dtmax)的恢复率均高于其他3组(P<0.01或P<0.05),HR的恢复率明显高于L0组(P<0.01),L0.03组、LG组与L0组比较心率(HR)、+dp/dtmax的恢复率差异无统计学意义(P>0.05),-dp/dtmax恢复率在T2时点高于L0组(P<0.05或P<0.01)。再灌注末CK和LDH漏出量L0.3组明显低于其他各组(P<0.05或P<0.01)。结论:Levo加入STH-2停搏液能够明显减轻缺血再灌注心肌的损伤。
Objective：To observe the protective effect of levosimendan（Levo） in cardioplegic solution on isolated rat heart.Methods：Thirty-two male Wistar rats were randomly divided into four groups：no Levo（L0） group,0.03 μmol/L Levo（L0.03） group,0.3 μmol/L Levo（L0.3） group,0.3 μmol/L Levo and 10 μmol/L glibenclamide（LG） group.The hearts was connected to Langendorff perfusion apparatus immediately after perfused with K-H solution for 30 minutes.Hearts were then perfused by different cardioplegic solutions at 25 ℃ for 2 h,and then were reperfused with K-H solution for 30 minutes.The changes of hemodynamics,myocardial enzyme leakage in the coronary effluent were observed.Results：There were no significant differences in hemodynsmics,creatine kinase（CK）and lactate dehydrogenase（LDH） before hearts stopped beating in all groups（P 0.05）.After reperfusion,the recovery values of heart rate（HR）,left ventricular developed pressure（LVDP）and the rate of pressure development（±dp/dtmax） were higher in group L0.3 than that of group L0（P 0.01）.There were no significant differences in the recovery values of HR and ±dp/dtmax between groups L0.03,LG and L0（P 0.05）.The recovery of ±dp/dtmax was higher at T2 in groups L0.03 and LG than that of group L0（P 0.05）.The levels of LDH and CK were significantly decreased at the end stage of reperfusion in group L0.3 compared with those of other groups（P 0.05）.Conclusion：There was a protective effect on myocardial ischemia-reperfusion injury with Levo added into STH-2 cardioplegic solution.
出处
《天津医药》
CAS
北大核心
2011年第9期831-834,共4页
Tianjin Medical Journal
